leisure time -WSS

leisure time

author：leisure time 2025-09-14 21:56:55 - browse：28922

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： What it’s like to watch children die of measles

focus

WSS

White House Covid adviser calls on docs to combat misinformation

'A game

FDA panel to weigh safety of artificial wombs for preterm births

Amylyx ALS drug fails large clinical trial

Amylyx ALS drug failure raises questions and concerns

In his State of the Union, Biden takes clear aim at 'Big Pharma'

entertainment

leisure time

knowledge

Jerome Adams on the need for new antivirals for Covid

Akili changes sales model for its ADHD video game treatment

Malaria cases in Florida and Texas: Here’s what you need to know

The drug industry has found itself all alone in Washington

Medicare details structure of new drug price negotiation program

Fed up with FDA, ALS advocates consider a take

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Free Covid tests will again be offered to all U.S. households

Moonlake's readout produced a cash windfall. Risks remain

The struggle to figure out which patients 'deserve' Wegovy

knowledge

FDA weighs limits of animal data in assessing artificial wombs

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

David Liu startup to focus on CRISPR delivery

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Akili changes sales model for its ADHD video game treatment

focus

hotspot

focus

focus